[Effect of angiotensin II receptor antagonist on heart failure]

Area of Science:

• Cardiology
• Pharmacology
• Clinical Trials

Background:

• Angiotensin II receptor antagonists like candesartan show promise in improving cardiac function.
• Existing treatments for heart failure, including ACE inhibitors, have limitations for some patients.

Purpose of the Study:

• To evaluate the efficacy of candesartan cilexetil in patients with heart failure.
• To compare candesartan's effect on heart failure progression against a placebo.

Main Methods:

• The Assessment of Response to Candesartan Heart Failure in Japan (ARCH-J) was a 6-month, randomized, double-blind, placebo-controlled study.
• 305 patients with heart failure, who were either ACE inhibitor-naive, inadequately controlled, or intolerant, were enrolled.
• Patients received either candesartan cilexetil (8 mg/day) or a placebo.

Main Results:

• Confirmed heart failure progression occurred in 7.4% of the candesartan group versus 22.2% in the placebo group (63.8% risk reduction).
• Cardiovascular events were significantly lower in the candesartan group (10.8%) compared to placebo (22.9%) (50.2% risk reduction).

Conclusions:

• Candesartan cilexetil at 8 mg/day significantly improved heart failure progression compared to placebo.
• Candesartan demonstrates a significant benefit in reducing cardiovascular events in heart failure patients.